Compare Stocks: APLS, NKTR, LEGN, and AVIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$41.03	$34.89	$16.10 ▼ $41.14	$5.25B	-0.24	7.54 million shs	68.61 million shs
AVIR Atea Pharmaceuticals	$4.11 -4.6%	$5.04	$2.87 ▼ $6.45	$345.68M	0.39	296,872 shs	349,862 shs
LEGN Legend Biotech	$21.63 -3.0%	$19.55	$16.24 ▼ $37.50	$4.32B	0.57	2.00 million shs	2.19 million shs
NKTR Nektar Therapeutics	$38.87 -0.8%	$55.69	$33.40 ▼ $109.00	$1.34B	1.26	1.15 million shs	600,920 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+36.54%
AVIR Atea Pharmaceuticals	-4.64%	+1.73%	-21.11%	-12.55%	+24.92%
LEGN Legend Biotech	-3.00%	+12.25%	+8.75%	+16.60%	-32.68%
NKTR Nektar Therapeutics	-0.79%	+4.43%	-35.79%	-45.00%	-34.81%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLS Apellis Pharmaceuticals	$41.03	$34.89	$16.10 ▼ $41.14	$5.25B	-0.24	7.54 million shs	68.61 million shs
AVIR Atea Pharmaceuticals	$4.11 -4.6%	$5.04	$2.87 ▼ $6.45	$345.68M	0.39	296,872 shs	349,862 shs
LEGN Legend Biotech	$21.63 -3.0%	$19.55	$16.24 ▼ $37.50	$4.32B	0.57	2.00 million shs	2.19 million shs
NKTR Nektar Therapeutics	$38.87 -0.8%	$55.69	$33.40 ▼ $109.00	$1.34B	1.26	1.15 million shs	600,920 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLS Apellis Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+36.54%
AVIR Atea Pharmaceuticals	-4.64%	+1.73%	-21.11%	-12.55%	+24.92%
LEGN Legend Biotech	-3.00%	+12.25%	+8.75%	+16.60%	-32.68%
NKTR Nektar Therapeutics	-0.79%	+4.43%	-35.79%	-45.00%	-34.81%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLS Apellis Pharmaceuticals	2.11	Hold	$38.00	-7.38% Downside
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	70.32% Upside
LEGN Legend Biotech	2.53	Moderate Buy	$54.69	152.85% Upside
NKTR Nektar Therapeutics	2.69	Moderate Buy	$130.67	236.16% Upside

Current Analyst Ratings Breakdown

Latest APLS, NKTR, LEGN, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	LEGN Legend Biotech	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/19/2026	LEGN Legend Biotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/15/2026	AVIR Atea Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/13/2026	LEGN Legend Biotech	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$74.00 ➝ $68.00
10/12/2026	NKTR Nektar Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Neutral	$53.00
10/12/2026	NKTR Nektar Therapeutics	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/12/2026	NKTR Nektar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$130.00
10/9/2026	LEGN Legend Biotech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Neutral	$35.00 ➝ $33.00
10/9/2026	NKTR Nektar Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$178.00
10/9/2026	NKTR Nektar Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Perform
10/8/2026	LEGN Legend Biotech	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$58.00 ➝ $56.00

(Data available from 10/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLS Apellis Pharmaceuticals	$1.11B	4.75	$0.21 per share	196.33	$3.24 per share	12.66
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
LEGN Legend Biotech	$1.27B	3.30	N/A	N/A	$5.43 per share	3.98
NKTR Nektar Therapeutics	$54.59M	24.31	N/A	N/A	$4.41 per share	8.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLS Apellis Pharmaceuticals	$22.39M	$1.02	40.23	N/A	N/A	12.06%	39.71%	13.20%	N/A
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
LEGN Legend Biotech	-$296.80M	-$0.25	N/A	18.65	N/A	-7.21%	-8.71%	-5.40%	11/10/2026 (Estimated)
NKTR Nektar Therapeutics	-$164.08M	-$6.70	N/A	N/A	N/A	-287.84%	-37.87%	-25.67%	11/12/2026 (Estimated)

Latest APLS, NKTR, LEGN, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	NKTR Nektar Therapeutics	-$2.07	N/A	N/A	N/A	$10.27 million	N/A
11/11/2026	Q3 2026	AVIR Atea Pharmaceuticals	-$0.51	N/A	N/A	N/A	$50.45 million	N/A
11/10/2026	Q3 2026	LEGN Legend Biotech	$0.01	N/A	N/A	N/A	$361.46 million	N/A
8/13/2026	Q2 2026	NKTR Nektar Therapeutics	-$1.97	-$1.23	+$0.74	-$1.23	$10.43 million	$10.13 million
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/11/2026	Q2 2026	LEGN Legend Biotech	$0.07	$0.09	+$0.02	$0.18	$355.96 million	$387.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLS Apellis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LEGN Legend Biotech	N/A	N/A	N/A	N/A	N/A
NKTR Nektar Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLS Apellis Pharmaceuticals	0.87	3.63	3.16
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
LEGN Legend Biotech	N/A	3.04	2.94
NKTR Nektar Therapeutics	N/A	10.42	10.42

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLS Apellis Pharmaceuticals	96.29%
AVIR Atea Pharmaceuticals	86.67%
LEGN Legend Biotech	70.89%
NKTR Nektar Therapeutics	75.88%

Insider Ownership

Company	Insider Ownership
APLS Apellis Pharmaceuticals	6.50%
AVIR Atea Pharmaceuticals	21.60%
LEGN Legend Biotech	0.02%
NKTR Nektar Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLS Apellis Pharmaceuticals	770	128.02 million	119.70 million	Optionable
AVIR Atea Pharmaceuticals	55	80.21 million	62.88 million	Optionable
LEGN Legend Biotech	2,965	193.77 million	193.73 million	Optionable
NKTR Nektar Therapeutics	63	34.14 million	33.29 million	Optionable

APLS, NKTR, LEGN, and AVIR Headlines

Recent News About These Companies

Nektar Therapeutics stock trades at 34.16 euros late Friday

October 30 at 8:57 PM | ad-hoc-news.deA

Nektar Therapeutics: Focus Returns To The Strengths Of The Company

October 30 at 12:31 PM | seekingalpha.com

Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?

October 29 at 11:06 AM | zacks.com

Nektar Therapeutics (NKTR) Projected to Announce Quarterly Earnings on Thursday

October 29 at 7:41 AM | marketbeat.com

UBS sets USD 53.00 target for Nektar Therapeutics stock

October 27, 2026 | ad-hoc-news.deA

Nektar Therapeutics to Announce Financial Results for the Third Quarter on Thursday, November 12, 2026, After Close of U.S.-Based Financial Markets

October 27, 2026 | prnewswire.com

Nektar Therapeutics (NKTR) - What Are Researchers Thinking About This Stock?

October 26, 2026 | americanbankingnews.com

Nektar Therapeutics (NASDAQ:NKTR) Stock Rated "Moderate Buy" by Wall Street Brokerages

October 26, 2026 | marketbeat.com

Nektar Therapeutics $NKTR Holdings Boosted by Iridian Asset Management LLC CT

October 25, 2026 | marketbeat.com

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 23, 2026 | prnewswire.com

BTIG keeps USD 178 target for Nektar Therapeutics stock

October 20, 2026 | ad-hoc-news.deA

Nektar Therapeutics stock trails UBS target by 32.49 percent on October 16

October 17, 2026 | ad-hoc-news.deA

Can Nektar's Pipeline Progress Create Long-Term Value Amid Rivalry?

October 15, 2026 | zacks.com

Nektar Therapeutics (NASDAQ:NKTR) Raised to "Hold" at UBS Group

October 14, 2026 | marketbeat.com

Leerink Partners initiates coverage of Nektar Therapeutics with outperform rating

October 13, 2026 | msn.com

Leerink Partners initiates coverage of Nektar Therapeutics at outperform

October 12, 2026 | msn.com

Nektar Therapeutics (NKTR) Could Be 71% Undervalued As Rezpegaldesleukin Data Extend Its Case

October 12, 2026 | finance.yahoo.com

Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Leerink Partners

October 12, 2026 | marketbeat.com

Raymond James initiates coverage of Nektar Therapeutics at market perform

October 10, 2026 | msn.com

Raymond James initiates coverage of Nektar Therapeutics with market perform

October 9, 2026 | msn.com

Nektar Therapeutics (NASDAQ:NKTR) Earns "Buy" Rating from BTIG Research

October 9, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS, NKTR, LEGN, and AVIR Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Atea Pharmaceuticals NASDAQ:AVIR

$4.11 -0.20 (-4.64%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$4.14 +0.03 (+0.73%)

As of 10/30/2026 07:09 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Legend Biotech NASDAQ:LEGN

$21.63 -0.67 (-3.00%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$21.56 -0.07 (-0.32%)

As of 10/30/2026 07:55 PM Eastern

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Nektar Therapeutics NASDAQ:NKTR

$38.87 -0.31 (-0.79%)

Closing price 10/30/2026 04:00 PM Eastern

Extended Trading

$38.75 -0.12 (-0.31%)

As of 10/30/2026 07:30 PM Eastern

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLS, NKTR, LEGN, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLS, NKTR, LEGN, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLS, NKTR, LEGN, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS, NKTR, LEGN, and AVIR Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Atea Pharmaceuticals NASDAQ:AVIR

Legend Biotech NASDAQ:LEGN

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLS, NKTR, LEGN, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLS, NKTR, LEGN, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLS, NKTR, LEGN, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLS, NKTR, LEGN, and AVIR Company Descriptions

Apellis Pharmaceuticals NASDAQ:APLS

Atea Pharmaceuticals NASDAQ:AVIR

Legend Biotech NASDAQ:LEGN

Nektar Therapeutics NASDAQ:NKTR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools